Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Jeena Sikho Lifecare Ltd

| Q2 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤7th Nov 25

Summary : Jeena Sikho Life Care reported strong Q2 FY'26 growth, driven by bed expansion and new products, while strategically focusing on private healthcare and international markets.

Management Perspective positive : "Our continuous hard work and effort has given a great result.""This expansional growth shows that we are strongly motivated.""I told you clearly that my goal is to become India's No. 1 healthcare provider company.""We are just over-delivering what we are saying.""We will put full effort in the future. The better the result, the better."

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY'26 revenue from operations grew 66% year-on-year to Rs. 190 crores.
  2. PAT jumped 121% year-on-year to Rs. 59 crores, with 15% quarter-over-quarter growth.
  3. EBITDA grew 129% year-on-year to Rs. 92 crores, maintaining a 48% margin.
  4. Total bed capacity increased to 2,802, achieving the year-end target in six months.
  5. Product segment revenue grew 78% year-on-year; services segment contributed 50% of revenue.

Future Growth Prospects

  1. Plan to launch 15-20 new OTC products, with 10 expected by FY'26 end.
  2. Targeting 7,000 to 10,000 beds within the next three to five years.
  3. Strategic tie-up with Chandan Diagnostic to boost patient footfall and health insurance business.
  4. Expanding into wellness centers, diagnostics, and increasing the distributor chain.
  5. International expansion is underway in Nepal and Dubai, with Kazakhstan entry planned.
  6. Launching 50 new hospitals under a franchise model without company investment.

Management Insights

  1. Focus is on increasing bed count, customer footfall in clinics, and e-segment delivery.
  2. Strong motivation to widely spread quality alternative healthcare services.
  3. Emphasizes prevention and teaching healthy lifestyles to avoid sickness.
  4. Committed to achieving financial targets despite seasonal fluctuations.
  5. Prioritizing private sector and health insurance business over government contracts.

Signs of Skepticism

  1. Management stated 40% margin is not sustainable, targeting 20-25% as healthy.
  2. Slow progress on college hospital tie-ups due to government formalities.
  3. Discrepancy in previous year's PAT figures due to Ind-AS migration and auditor changes.
  4. Management's initial reluctance to discuss the new franchise model.

Risk Factors

  1. Slow government business payments lead to reduced focus on this segment.
  2. Government formalities and NOCs delay progress on college hospital tie-ups.
  3. Seasonal factors like cold weather and festivals can affect hospital occupancy rates.
  4. Current high profit margins (40%) are not sustainable; 20-25% is the healthy target.

Good To Know

  1. Financial reports for Q2 FY'26 were audited by Grant Thornton; company migrated to Ind-AS.
  2. Salesforce integration improved lead generation, data segregation, and customer feedback.
  3. Developing AI-dubbed videos in regional languages for broader patient reach.
  4. Planning a VIP premium center for investors and business-class patients.
  5. OTC products are undergoing clinical trials and have Ayush approval.

Key Drivers

  1. New OTC products to boost sales.
  2. Chandan tie-up to increase footfall.
  3. Aggressive bed capacity expansion continues.
  4. International market penetration progressing well.

Key Analyst Discussions

Competitive Environment

  1. Company differentiates by focusing on prevention, lifestyle, and detox through Panchkarma.
  2. Aims to be India's, then Asia's, then world's No.1 naturopathy and Ayurveda company.
  3. New OTC products are unique, having undergone clinical trials in Ayurveda.

Market Trends & Consumer Behavior

  1. Festival season (Diwali) impacts hospital occupancy as patients take leave.
  2. OTC business provided a "covering" during festival months.
  3. Increasing private insurance business due to issues with government payments.

Financial Highlights

  1. Current PAT margin is 31%, but management targets 20-25% as healthy.
  2. Q2 FY'26 revenue per bed is Rs. 8,324, with 57% occupancy.
  3. FY'26 revenue guidance maintained at Rs. 650-700 crores despite strong H1.
  4. Q3 is expected to be weaker due to cold weather and festival season.

Product Composition

  1. Pet Shuddhi kit sales are increasing, launched in multiple states.
  2. Planning 15-20 new OTC products, including BP, sugar, kidney, liver, depression medicines.
  3. OTC products will have 18-22% PAT margin, similar to overall company target.

Strategic Considerations

  1. Chandan Diagnostic tie-up offers free basic blood tests, cashback, and increased footfall.
  2. Only one of three planned medical college takeovers is operational (90% occupancy).
  3. International expansion in Nepal and Dubai is profitable; Kazakhstan tie-up planned.
  4. Planning 50 new franchise hospitals, company will not invest.